BPIQ Pro/Elite/Apex Investor Posts

Nearing 5 yrs since Reduce- It results

BIOPHARMA STOCK NEWS FLASH

Consistent with top 36 biopharma hedge funds

Conclusion: Mixed positive Positives: Efficacy ACU193 appears to reduce plaque @ highest dose levels AFAIK 1st time plaque reduction shown by binding oligomers ABOS concludes plaque reduction similar to “approved BA Abs” Plaque clearance data only out to ~3 months so hard to know Donanemab is probably best at clearing plaque ( See comparative table ) Serum pK looks good for monthly dosing Assay Csf target engagement assay Looks like it works well enough to help clin dev Impre

But, which is the best?

Overview: • One of my favorite under the radar companies • Huge upside • Difficult FDA approval behind them ⇒ Typical for drug device combo ⇒ 2 CRLs • But still high risk/high reward stock Details: Single drug company • Furoscix ⇒ SubQ furosemide via on body infusor ⇒ Diuretic for fluid build up in chronic heart failure • Early commercial - Launched Feb ‘23 • Market opp $7B Sales Pitch: Large cost savings for Medicare & insurers ✔️Patients stay home instead of IV @ ho

Intro:

Is $GRTX a buy into PDUFA - Aug 9, 2023?

ALHEIMER’S BREAKTHROUGH

PDSB

Summary:

SUMMARY

What is the upcoming event?

SUMMARY

ITCI is up over 33% since our Jan 31, 2023 Amp stock play (Read Post HERE) (FIG. 1)

Summary:

Summary:

Summary:

We have compiled a list of all smid-cap biopharma PDUFA decisions since September 2021 for your use!

$ASND announced it received a CRL on 4/28/23